What is ImmuneBridge?
ImmuneBridge specializes in the creation of high-quality cell therapies, utilizing umbilical cord blood stem cells. The company employs advanced machine learning for efficient donor screening and scalable manufacturing processes. Their proprietary technology is designed to overcome critical challenges in cell therapy, such as high costs and manufacturing complexities, with the goal of delivering safe and effective treatments. ImmuneBridge actively collaborates with academic and industry partners to pioneer innovative therapies for diseases that are currently untreatable, aiming to make cell therapies globally accessible and affordable.
How much funding has ImmuneBridge raised?
ImmuneBridge has raised a total of $12M across 1 funding round:
Angel/Seed
$12M
Angel/Seed (2023): $12M with participation from Merck Ventures, Gaingels, One Way Ventures, and Insight Partners
Key Investors in ImmuneBridge
Merck Ventures
Merck Ventures is the corporate venture capital arm of Merck, focused on investing in innovative technologies that can significantly impact the company's core business areas. They actively engage with their portfolio companies to drive commercial success.
Gaingels
Gaingels is a leading investment syndicate supporting the LGBTQ community and allies in venture capital, investing in companies with LGBT founders and inclusive teams across various sectors.
One Way Ventures
One Way Ventures is dedicated to backing immigrant founders in building high-impact global companies, believing that borders should not limit human potential.
What's next for ImmuneBridge?
The recent major strategic investment positions ImmuneBridge for significant scaling and further development of its cell therapy pipeline. This capital is expected to accelerate the company's efforts in clinical trials, manufacturing capacity expansion, and strategic partnerships. By addressing the core issues of cost and manufacturability, ImmuneBridge is poised to enhance the accessibility of life-changing cell therapies, potentially marking a new era in regenerative medicine.
See full ImmuneBridge company page
